<DOC>
	<DOC>NCT00755807</DOC>
	<brief_summary>This study is designed to primarily assess the efficacy and safety of duloxetine 60-120 mg once daily (QD) compared with placebo on the reduction of pain severity in participants with central neuropathic pain due to Multiple Sclerosis.</brief_summary>
	<brief_title>Duloxetine for Multiple Sclerosis Pain</brief_title>
	<detailed_description>Study is a multicenter, randomized, double-blind, parallel, placebo-controlled, 20-week trial with 4 study periods. Participants who screen successfully (Study Period I) will be randomized in a 1:1 fashion to duloxetine 60 mg QD or placebo. Starting with Study Period II, participants will be treated in a double-blind manner for 6 weeks. Participants who complete the 6-week, double-blind period will have the opportunity to participate in a 12-week, open-label, flexible-dose portion of the study (Study Period III). Study Period IV is a taper phase designed to reduce the occurrence of discontinuation adverse events. Participants may enter Study Period IV at any time after Visit 3.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Have central neuropathic pain due to multiple sclerosis (MS) based on the disease diagnostic criteria Adult males or females Have a score of 4 or greater on the daily 24hour average pain score Females must test negative for pregnancy at study entry Complete the daily diaries for at least 70% of the days of the study Participants may continue other prescription and nonprescription analgesic pain medications as long as the dose has been stable for 1 month prior to study entry, and they agree to maintain that stable dose throughout the study Disease Diagnostic Criteria: Diagnosis of MS at least 1 year prior to study entry No MS flares or change in disease treatment for the 3 months prior to study entry Daily pain due to MS for a minimum of 3 months prior to study entry Are currently in a clinical trial of MS diseasemodifying therapy Have pain that cannot be clearly differentiated from causes other than MS Any current or historical diagnosis of mania, bipolar disorder, psychosis, or schizoaffective disorder History of substance abuse or dependence Are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Central Neuropathic Pain</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>